Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00002474

NCT00002474
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with ovarian epithelial cancer that has come back or stopped responding to treatment
  • You have previously been treated with a chemotherapy drug called cisplatin or carboplatin, and it did not work
  • Your cancer can be measured or tracked — this can include blood test results (CA-125), or fluid build-up in the chest or abdomen that contains cancer cells
  • A sample of your bone marrow has been collected (harvested) before joining the study, and a large enough amount was obtained
  • Your bone marrow collection sites show no signs of cancer (confirmed by bone marrow samples, X-ray, and bone scan)
  • You are under 65 years old
  • You are reasonably active and able to care for yourself (confirm with trial site)
  • You are expected to live for at least 8 weeks
  • Your blood counts are at acceptable levels — including white blood cells, platelets, and haemoglobin
  • Your liver is functioning well enough, based on blood tests
  • Your kidneys are working well enough, based on a kidney function test
  • Your heart is pumping properly, confirmed by a specific heart scan
  • You are not currently pregnant, and a pregnancy test is negative
  • You do not have HIV
  • You are healthy enough to have a general anaesthetic

Who may not be able to join:

  • You have had a bone marrow transplant in the past
  • You have had previous bleeding or inflammation of the bladder (a condition called haemorrhagic cystitis)
  • You have significant hearing loss, particularly with voice-level sounds
  • You have an active infection at the time of joining
  • There are psychological reasons that would make this treatment unsuitable for you (confirm with trial site)
  • You have had chemotherapy, radiotherapy, or other biological treatments less than 4 weeks ago (or less than 6 weeks ago for certain specific chemotherapy drugs), or you have not yet fully recovered from those treatments

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Loyola University
Registry
clinicaltrials_gov
Start date
1 February 1991

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Response rate; Response duration; Overall survival; Nonhematopoietic toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov